Company profile

Chiesi Farmaceutici

Privately held: no public share price

Assets

(6 total)
6Total Assets
4Approved
1Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
Approved
Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3Small molecule
Asthma
Cangrelor(Kengreal)
Approved
P2Y12 receptorSmall molecule
Atherosclerotic Cardiovascular Disease
Lomitapide(Juxtapid)
Approved
MTPSmall molecule
Atherosclerotic Cardiovascular Disease
metreleptin(Myalept)
Approved
LeptinProtein / enzyme therapeutic
Obesity
Beclomethasone dipropionate/formoterol fumarate
Phase 3
Glucocorticoid receptor / Beta-2 adrenergic receptorSmall molecule
Asthma
Melevodopa/carbidopa (Sirio)(Sirio)No recent activity
Phase 2
dopamine precursorSmall molecule
Parkinson's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.